Answers are grounded in this paper and cite their sources.
Racemic 3-(4,4-diphenyl-4-silapiperidin-1-yl)propyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate ( rac -sila-niguldipine, rac - 1b ), a sila analogue of the calcium antagonist rac -niguldipine ( rac - 1a ), and the sila-niguldipine derivatives rac - 2b − rac - 4b were synthesized in multistep syntheses, starting from dichlorodiphenylsilane. The silicon compounds rac - 1b − rac - 4b contain a 4,4-diphenyl-4-silapiperidin-1-yl group instead of the 4,4-diphenylpiperidin-1-yl moiety in the parent carbon compound rac - 1a . rac -Sila-niguldipine and the precursor 3-(4,4-diphenyl-4-silapiperidin-1-yl)propanol ( 11 ) were structurally characterized by single-crystal X-ray diffraction. The pharmacological profiles of rac - 1b − rac - 4b were compared with that of rac - 1a across a range of receptor binding assays (radioligand binding studies at α 1A and α 2 adrenoceptors, the L-type Ca 2+ channel, and the serotonin 5-HT receptor). The silicon compounds rac - 2b − rac - 4b exhibit a profile similar to that of SNAP 5089 and therefore may be of potential benefit in the treatment of diseases such as benign prostatic hyperplasia (BPH).
No takes yet. Share an insight, caveat, or question.
Heinrich et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: